Skip to main content
CLOV
NASDAQ Finance

Clover Health Reports First Profitable Quarter, Projects Full-Year GAAP Net Income for 2026

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$2.7
Mkt Cap
$1.406B
52W Low
$1.58
52W High
$3.92
Market data snapshot near publication time

summarizeSummary

Clover Health announced strong Q1 2026 results, achieving positive GAAP Net Income for the first time and projecting full-year GAAP Net Income profitability, driven by significant revenue and membership growth.


check_boxKey Events

  • Achieves Q1 GAAP Net Income

    Clover Health reported GAAP Net Income of $27.3 million for Q1 2026, a significant improvement from a net loss of $1.3 million in Q1 2025.

  • Projects Full-Year GAAP Profitability

    The company provided full-year 2026 guidance for GAAP Net Income between $0 million and $20 million, indicating an expectation to achieve its first full year of GAAP Net Income profitability.

  • Strong Revenue and Membership Growth

    Total revenues increased 62.1% year-over-year to $749.2 million, while Medicare Advantage membership grew 51% to 155,773 members in Q1 2026.

  • Positive Adjusted EBITDA

    Adjusted EBITDA for Q1 2026 was $40.3 million, up 56.2% from $25.8 million in the prior year period.


auto_awesomeAnalysis

Clover Health's Q1 2026 results mark a significant turnaround, with the company achieving positive GAAP Net Income for the first time, a substantial improvement from a net loss in the prior year. This positive performance is further bolstered by strong growth across key metrics, including a 62% year-over-year increase in total revenues and a 51% rise in Medicare Advantage membership. The company's guidance for full-year 2026 GAAP Net Income profitability is a critical development, signaling a potential shift in its financial trajectory after a period of losses, as highlighted by the negative financial baseline from the last 10-K and the impact on 2025 executive compensation. Investors should monitor the company's ability to sustain this profitability and meet its full-year guidance.

At the time of this filing, CLOV was trading at $2.70 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.58 to $3.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CLOV - Latest Insights

CLOV
May 08, 2026, 8:11 AM EDT
Source: Wiseek News
Importance Score:
8
CLOV
May 08, 2026, 8:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
CLOV
May 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
CLOV
Apr 28, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
CLOV
Apr 01, 2026, 8:32 AM EDT
Filing Type: 8-K
Importance Score:
7
CLOV
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CLOV
Mar 10, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
8
CLOV
Mar 10, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
CLOV
Mar 06, 2026, 9:06 AM EST
Filing Type: 8-K/A
Importance Score:
8
CLOV
Feb 27, 2026, 8:08 AM EST
Filing Type: 10-K
Importance Score:
8